Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
Merck
Baxter
Express Scripts
AstraZeneca

Last Updated: January 17, 2020

DrugPatentWatch Database Preview

Dacomitinib - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for dacomitinib and what is the scope of patent protection?

Dacomitinib is the generic ingredient in one branded drug marketed by Pfizer Inc and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dacomitinib has fifty-three patent family members in forty-four countries.

Two suppliers are listed for this compound.

Summary for dacomitinib
International Patents:53
US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 2
Bulk Api Vendors: 67
Clinical Trials: 24
Patent Applications: 2
DailyMed Link:dacomitinib at DailyMed
Recent Clinical Trials for dacomitinib

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Centre, SingaporePhase 2
Memorial Sloan Kettering Cancer CenterPhase 1
Memorial Sloan Kettering Cancer CenterEarly Phase 1

See all dacomitinib clinical trials

Synonyms for dacomitinib
(2E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide
(2e)-N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-Methoxyquinazolin-6-Yl}-4-(Piperidin-1-Yl)but-2-Enamide
(E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enaMide
(E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-(piperidin-1-yl)but-2-enamide
(E)-N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
1110813-31-4
1110813-31-4 pound not PF 299804 pound not PF-299804
2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, (2E)-
2XJX250C20
AB0035896
ABP000126
AC-25915
AKOS025401818
AOB87383
AOB87735
BC261945
BCP02530
BDBM112499
C24H25ClFN5O2
CHEBI:132268
CHEBI:91466
CHEMBL2110732
CS-0500
D09883
D5450
Dacomitinib (INN)
Dacomitinib (PF299804, PF-00299804)
Dacomitinib (PF299804, PF299)
Dacomitinib (PF299804)
Dacomitinib [USAN:INN]
Dacomitinib anhydrous
Dacomitinib, PF299804
dacomitinibum
DB11963
DTXSID50149493
EX-A030
GTPL7422
HY-13272
J-500784
MFCD19443734
MLS006011275
NCGC00263185-09
PF 00299804
PF 00299804-03
PF-00299804
PF-00299804 dacomitinib
PF-00299804-03
PF-299
PF-299804
PF-299804 (Dacomitinib PF-00299804)
pf00299804
PF299
PF299804
PF299804|||PF299
Q-4059
QCR-174
RL00451
s2727
SB21754
SC-94589
SMR004703025
SW219155-1
UNII-2XJX250C20
US8623883, No. 2
Vizimpro
Y0338
ZINC72266312

US Patents and Regulatory Information for dacomitinib

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-001 Sep 27, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-003 Sep 27, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-003 Sep 27, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-002 Sep 27, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-002 Sep 27, 2018 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-003 Sep 27, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Pfizer Inc VIZIMPRO dacomitinib TABLET;ORAL 211288-001 Sep 27, 2018 RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for dacomitinib

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1746999 301004 Netherlands   Start Trial PRODUCT NAME: DACOMITINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, SOLVAAT OF HYDRAAT ERVAN, IN HET BIJZONDER DACOMITINIB MONOHYDRAAT; REGISTRATION NO/DATE: EU/1/19/1354 20190404
1746999 2019C/540 Belgium   Start Trial PRODUCT NAME: DACOMITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1354 20190404
1746999 PA2019016 Lithuania   Start Trial PRODUCT NAME: DAKOMITINIBO MONOHIDRATAS; REGISTRATION NO/DATE: EU/1/19/1354 20190402
1746999 LUC00127 Luxembourg   Start Trial PRODUCT NAME: DACOMITINIB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VIZIMPRO ); AUTHORISATION NUMBER AND DATE: EU/1/19/1354 20190404
1746999 CR 2019 00043 Denmark   Start Trial PRODUCT NAME: DACOMITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/19/1354 20190404
1746999 122019000080 Germany   Start Trial PRODUCT NAME: DACOMITINIB-MONOHYDRAT; REGISTRATION NO/DATE: EU/1/19/1354 20190402
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Johnson and Johnson
Moodys
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.